Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Auction 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Terns Pharmaceuticals, Inc.
< Previous
1
2
Next >
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
May 03, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
April 29, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
April 10, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
March 14, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
March 11, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
March 07, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
February 27, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)
February 07, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer
February 07, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
February 02, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
January 03, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
November 29, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer
November 27, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates
November 14, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023
November 13, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
November 09, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
November 03, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity
November 02, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals to Participate in Upcoming Investor Conferences
October 19, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia
October 16, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
October 03, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
September 06, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences
September 05, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates
August 08, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH
August 08, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
August 03, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Announces Leadership Transition
August 03, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia
July 18, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
July 05, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.